trans-Resveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats

J Agric Food Chem. 2010 Jul 14;58(13):8104-10. doi: 10.1021/jf100702x.

Abstract

trans-Resveratrol, a natural occurring polyphenol, has been described as an antiproliferative and proapoptotic agent in vitro. Here, we studied the effect of trans-resveratrol administered orally at a dose of 60 mg/kg for 49 days on early preneoplastic markers induced by the intraperitoneal injection of 1,2-dimethylhydrazine (20 mg/kg). We measured trans-resveratrol and its derivates by liquid-liquid extraction followed by high-performance liquid chromatography diode array detection analysis in colon contents. Dihydroresveratrol was the most abundant compound in the colon, followed by trans-resveratrol glucuronide and small amounts of trans-resveratrol and its sulfate. The administration of trans-resveratrol decreased aberrant crypt foci by 52%, and mucin depleted foci by 45% in colon. In conclusion, the correlation between the reduction of precancerous colonic lesions and the availability of trans-resveratrol in the colon provides a new insight into the therapeutical potential of this polyphenol and its metabolites.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1,2-Dimethylhydrazine / adverse effects
  • Animals
  • Colon / chemistry
  • Colon / drug effects
  • Colon / metabolism
  • Colon / pathology
  • Colonic Neoplasms / chemically induced
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / pathology*
  • Disease Models, Animal
  • Humans
  • Male
  • Precancerous Conditions / pathology
  • Rats
  • Rats, Sprague-Dawley
  • Resveratrol
  • Stilbenes / administration & dosage*
  • Stilbenes / chemistry
  • Stilbenes / metabolism

Substances

  • Stilbenes
  • 1,2-Dimethylhydrazine
  • Resveratrol